JPWO2021094562A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021094562A5 JPWO2021094562A5 JP2022525171A JP2022525171A JPWO2021094562A5 JP WO2021094562 A5 JPWO2021094562 A5 JP WO2021094562A5 JP 2022525171 A JP2022525171 A JP 2022525171A JP 2022525171 A JP2022525171 A JP 2022525171A JP WO2021094562 A5 JPWO2021094562 A5 JP WO2021094562A5
- Authority
- JP
- Japan
- Prior art keywords
- antigenic peptide
- cell
- antigenic
- treatment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 51
- 230000000890 antigenic effect Effects 0.000 claims 43
- 210000003719 b-lymphocyte Anatomy 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 230000036210 malignancy Effects 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000002163 immunogen Effects 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 108020004707 nucleic acids Proteins 0.000 claims 7
- 102000039446 nucleic acids Human genes 0.000 claims 7
- 150000007523 nucleic acids Chemical class 0.000 claims 7
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 208000011778 T-cell/histiocyte rich large B cell lymphoma Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 230000003308 immunostimulating effect Effects 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 108020004491 Antisense DNA Proteins 0.000 claims 1
- 108020005544 Antisense RNA Proteins 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 108020004394 Complementary RNA Proteins 0.000 claims 1
- 101800000324 Immunoglobulin A1 protease translocator Proteins 0.000 claims 1
- 241000736262 Microbiota Species 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 206010036711 Primary mediastinal large B-cell lymphomas Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003816 antisense DNA Substances 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Claims (32)
ＰｅｐＮｔ－ＣＯＲＥ－ＰｅｐＣｔ （Ｉ）PepNt-CORE-PepCt (I)
（式中、(In the formula,
－「ＰｅｐＮｔ」は、０～５００個のアミノ酸残基の長さを有するポリペプチドからなり、前記式（Ｉ）のポリペプチドのＮ末端に位置し、- "PepNt" consists of a polypeptide having a length of 0 to 500 amino acid residues and is located at the N-terminus of the polypeptide of formula (I),
－ＣＯＲＥは、請求項１から１１のいずれかに定義される抗原性ペプチドからなり、- the CORE consists of an antigenic peptide as defined in any of claims 1 to 11;
－「ＰｅｐＣｔ」は、０～５００個のアミノ酸残基の長さを有するポリペプチドからなり、前記式（Ｉ）のポリペプチドのＣ末端に位置する。）- "PepCt" consists of a polypeptide having a length of 0 to 500 amino acid residues and is located at the C-terminus of the polypeptide of formula (I) above. )
－請求項１から１１のいずれかに記載の抗原性ペプチド、- an antigenic peptide according to any one of claims 1 to 11;
－請求項１２から１５のいずれかに記載の免疫原性化合物、- an immunogenic compound according to any of claims 12 to 15,
－請求項１６又は１７に記載の抗原提示細胞、- the antigen presenting cell according to claim 16 or 17;
－請求項１８又は１９に記載の核酸、- the nucleic acid according to claim 18 or 19,
－請求項２０に記載の宿主細胞、及び／又は- a host cell according to claim 20, and/or
－請求項２１に記載の細胞傷害性Ｔリンパ球、- cytotoxic T lymphocytes according to claim 21;
を含むことを特徴とする、Ｂ細胞悪性腫瘍の治療用医薬組成物。A pharmaceutical composition for treating B-cell malignant tumor, comprising:
（ｉｉ）請求項１２から１５のいずれかに記載の免疫原性化合物である少なくとも２つの異なる免疫原性化合物；(ii) at least two different immunogenic compounds which are immunogenic compounds according to any of claims 12 to 15;
（ｉｉｉ）請求項１６又は１７に記載の抗原提示細胞である少なくとも２つの異なる抗原提示細胞；(iii) at least two different antigen presenting cells which are antigen presenting cells according to claim 16 or 17;
（ｉｖ）請求項１８又は１９に記載の核酸である少なくとも２つの異なる核酸；(iv) at least two different nucleic acids which are the nucleic acids of claim 18 or 19;
（ｖ）請求項２０に記載の宿主細胞である少なくとも２つの異なる宿主細胞；又は(v) at least two different host cells which are host cells according to claim 20; or
（ｖｉ）請求項２１に記載の細胞傷害性Ｔリンパ球である少なくとも２つの異なる細胞傷害性Ｔリンパ球、(vi) at least two different cytotoxic T lymphocytes, which are the cytotoxic T lymphocytes of claim 21;
を含む、請求項２２に記載のＢ細胞悪性腫瘍の治療用医薬組成物。The pharmaceutical composition for treating B cell malignancy according to claim 22, comprising:
－配列番号１１０で表されるアミノ酸配列を含む又はからなる抗原性ペプチド；- an antigenic peptide comprising or consisting of the amino acid sequence represented by SEQ ID NO: 110;
－配列番号１１４で表されるアミノ酸配列を含む又はからなる抗原性ペプチド；- an antigenic peptide comprising or consisting of the amino acid sequence represented by SEQ ID NO: 114;
－配列番号２２０で表されるアミノ酸配列を含む又はからなる抗原性ペプチド；及び- an antigenic peptide comprising or consisting of the amino acid sequence represented by SEQ ID NO: 220; and
－任意に、配列番号６５で表されるアミノ酸配列を含む又はからなる抗原性ペプチド、- optionally an antigenic peptide comprising or consisting of the amino acid sequence represented by SEQ ID NO: 65,
に関する、請求項２６に記載のＢ細胞悪性腫瘍の治療用医薬組成物。27. The pharmaceutical composition for the treatment of B cell malignancy according to claim 26.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19306475 | 2019-11-15 | ||
| EP19306475.5 | 2019-11-15 | ||
| EPPCT/EP2020/079257 | 2020-10-16 | ||
| EP2020079257 | 2020-10-16 | ||
| PCT/EP2020/082101 WO2021094562A2 (en) | 2019-11-15 | 2020-11-13 | Antigenic peptides for prevention and treatment of b-cell malignancy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023501204A JP2023501204A (en) | 2023-01-18 |
| JPWO2021094562A5 true JPWO2021094562A5 (en) | 2023-12-11 |
Family
ID=75911928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022525171A Pending JP2023501204A (en) | 2019-11-15 | 2020-11-13 | Antigenic peptides for the prevention and treatment of B-cell malignancies |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11759508B2 (en) |
| EP (2) | EP4357356A2 (en) |
| JP (1) | JP2023501204A (en) |
| CN (1) | CN114746112A (en) |
| AU (1) | AU2020384926A1 (en) |
| BR (1) | BR112022009100A2 (en) |
| CA (1) | CA3153470A1 (en) |
| DK (1) | DK4021487T3 (en) |
| FI (1) | FI4021487T3 (en) |
| HR (1) | HRP20240116T1 (en) |
| HU (1) | HUE065075T2 (en) |
| LT (1) | LT4021487T (en) |
| MX (1) | MX2022005704A (en) |
| PL (1) | PL4021487T3 (en) |
| RS (1) | RS65262B1 (en) |
| SI (1) | SI4021487T1 (en) |
| WO (1) | WO2021094562A2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102622188B1 (en) | 2016-10-07 | 2024-01-05 | 엔터롬 에스.에이. | Immunogenic Compounds for Cancer Treatment |
| EP3522917A2 (en) | 2016-10-07 | 2019-08-14 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| US11478538B2 (en) | 2016-10-07 | 2022-10-25 | Enterome S.A. | Immunogenic compounds for cancer therapy |
| WO2023167213A1 (en) * | 2022-03-01 | 2023-09-07 | ｂｉｔＢｉｏｍｅ株式会社 | Method, program, and recording medium for identifying amino acid residue sequence |
| KR20240017325A (en) * | 2022-07-29 | 2024-02-07 | 주식회사 엘지화학 | Recombinant fusion protein for antigen delivery and uses thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3841091A1 (en) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | SYNTHETIC ANTIGENS, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| EP0378881B1 (en) | 1989-01-17 | 1993-06-09 | ENIRICERCHE S.p.A. | Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines |
| IT1237764B (en) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | SYNTHETIC PEPTIDES USEFUL AS UNIVERSAL CARRIERS FOR THE PREPARATION OF IMMUNOGENIC CONJUGATES AND THEIR USE FOR THE DEVELOPMENT OF SYNTHETIC VACCINES. |
| IT1262896B (en) | 1992-03-06 | 1996-07-22 | CONJUGATE COMPOUNDS FORMED FROM HEAT SHOCK PROTEIN (HSP) AND OLIGO-POLY-SACCHARIDES, THEIR USE FOR THE PRODUCTION OF VACCINES. | |
| US5635363A (en) | 1995-02-28 | 1997-06-03 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for the detection, quantitation and purification of antigen-specific T cells |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| PL203917B1 (en) | 1999-03-19 | 2009-11-30 | Glaxosmithkline Biolog Sa | Vaccine |
| AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| FR2798128B1 (en) | 1999-09-06 | 2001-11-16 | Inst Nat Sante Rech Med | MEANS OF DETECTION AND PURIFICATION OF T CD8 + LYMPHOCYTE POPULATIONS SPECIFIC TO PEPTIDES PRESENT IN THE HLA CONTEXT |
| US7812116B2 (en) * | 2003-07-03 | 2010-10-12 | Rush University Medical Center | Immunogenic peptides |
| HUE024541T2 (en) | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Novel and powerful MHC-class II peptides derived from survivin and neurocan |
| WO2013040142A2 (en) * | 2011-09-16 | 2013-03-21 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
| EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| WO2013101690A1 (en) | 2011-12-29 | 2013-07-04 | modeRNA Therapeutics | Modified mrnas encoding cell-penetrating polypeptides |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
| WO2017184590A1 (en) * | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
| CN106008695A (en) * | 2016-06-19 | 2016-10-12 | 苏州普罗达生物科技有限公司 | CD19 immunogen polypeptide and application thereof |
| WO2019051001A1 (en) * | 2017-09-06 | 2019-03-14 | California Institute Of Technology | Signaling and antigen-presenting bifunctional receptors (sabr) |
| CA3075363A1 (en) * | 2017-10-09 | 2019-04-18 | Enterome S.A. | Microbiota sequence variants of tumor-related antigenic epitopes |
| FI3773689T3 (en) * | 2018-04-11 | 2023-01-31 | Antigenic peptides for prevention and treatment of cancer | |
| WO2020072700A1 (en) * | 2018-10-02 | 2020-04-09 | Dana-Farber Cancer Institute, Inc. | Hla single allele lines |
-
2020
- 2020-11-13 SI SI202030352T patent/SI4021487T1/en unknown
- 2020-11-13 HR HRP20240116TT patent/HRP20240116T1/en unknown
- 2020-11-13 LT LTEPPCT/EP2020/082101T patent/LT4021487T/en unknown
- 2020-11-13 EP EP23220228.3A patent/EP4357356A2/en active Pending
- 2020-11-13 CA CA3153470A patent/CA3153470A1/en active Pending
- 2020-11-13 CN CN202080083161.5A patent/CN114746112A/en active Pending
- 2020-11-13 EP EP20804279.6A patent/EP4021487B1/en active Active
- 2020-11-13 HU HUE20804279A patent/HUE065075T2/en unknown
- 2020-11-13 RS RS20240132A patent/RS65262B1/en unknown
- 2020-11-13 JP JP2022525171A patent/JP2023501204A/en active Pending
- 2020-11-13 FI FIEP20804279.6T patent/FI4021487T3/en active
- 2020-11-13 WO PCT/EP2020/082101 patent/WO2021094562A2/en active Application Filing
- 2020-11-13 DK DK20804279.6T patent/DK4021487T3/en active
- 2020-11-13 AU AU2020384926A patent/AU2020384926A1/en active Pending
- 2020-11-13 PL PL20804279.6T patent/PL4021487T3/en unknown
- 2020-11-13 BR BR112022009100A patent/BR112022009100A2/en unknown
- 2020-11-13 MX MX2022005704A patent/MX2022005704A/en unknown
-
2022
- 2022-05-02 US US17/734,694 patent/US11759508B2/en active Active
-
2023
- 2023-07-19 US US18/354,966 patent/US20240033335A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1659179B1 (en) | Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination | |
| JP5230579B2 (en) | Cancer antigen based on the product of the tumor suppressor gene WT1 | |
| JP4227407B2 (en) | Vaccine composition | |
| JP2002514658A (en) | β-amyloid precursor protein and frameshift variants of ubiquitin B and uses thereof | |
| JP2008222721A6 (en) | Vaccine composition | |
| Oki et al. | Heat shock protein-based cancer vaccines | |
| JP2017525336A5 (en) | ||
| JP2012500001A5 (en) | ||
| JP2010523471A5 (en) | ||
| JP2003510334A (en) | Stress protein compositions and methods for prevention and treatment of cancer and infectious diseases | |
| JPWO2021163438A5 (en) | ||
| JPWO2021094562A5 (en) | ||
| JP2012513742A5 (en) | ||
| Tohumeken et al. | A modular antigen presenting peptide/oligonucleotide nanostructure platform for inducing potent immune response | |
| JP2007126442A (en) | Cancer specific antigen | |
| JP6871432B2 (en) | HLA-A2 subtype-specific antigenic determinant derived from HLA-A2 that induces an antigen-specific T cell immune response to the PLK1 protein | |
| JP2013513549A5 (en) | ||
| WO2023163094A1 (en) | Pharmaceutical composition for treatment or prevention of adult t-cell leukemia | |
| JP2012510794A5 (en) | ||
| WO2023049921A1 (en) | Pd-l1 inhibitory peptide for cancer immunotherapy | |
| US7314626B2 (en) | Use of peptide vectors to improve the immune response to antigens | |
| Melief et al. | The Promise of T Cell Immunotherapy of Cancer | |
| AU2002340561A1 (en) | Use of peptide vectors to improve the immune response to antigens |